Physician profile
Binu Bashyal
NPI 1669251617
$3,771.67
in general payments reported to CMS, 2019-2025
33 companies · $2,373 in 2025
The $2,373 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $286 · 2024: $1,112 · 2025: $2,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,688 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,687.67 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $582.55 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $301.51 | 2025 | Entyvio, Gattex, Eohilia |
| Teva Pharmaceuticals USA, INC. | $268.20 | 2023-2024 | Austedo Xr, Ajovy |
| Celltrion USA INC. | $251.25 | 2025 | Zymfentra, Vegzelma |
| Janssen Biotech, INC. | $249.55 | 2025 | Tremfya |
| Qol Medical, LLC | $189.75 | 2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $188.42 | 2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.39 | 2025 | Xifaxan |
| Sk Life Science, INC. | $186.27 | 2023-2024 | |
| Ucb, INC. | $146.45 | 2024 | Briviact, Fintepla, Rystiggo |
| Ardelyx, INC. | $145.95 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $138.46 | 2025 | Voquezna |
| Neurocrine Biosciences, INC. | $119.89 | 2023-2024 | Ingrezza, Ongentys |
| Genentech USA, INC. | $115.32 | 2023-2024 | Ocrevus, Enspryng |
| Genzyme Corporation | $109.56 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $68.78 | 2024-2025 | Omvoh, Emgality, Reyvow |
| Novartis Pharmaceuticals Corporation | $62.85 | 2023-2024 | |
| Eisai INC. | $55.75 | 2024 | |
| Merz Pharmaceuticals, LLC | $54.76 | 2023-2024 | Xeomin |
| Tanabe Pharma America, INC. | $50.77 | 2023-2024 | |
| Madrigal Pharmaceuticals | $49.59 | 2025 | Rezdiffra |
| Mallinckrodt Hospital Products INC. | $42.62 | 2025 | Terlivaz |
| Novo Nordisk INC | $26.45 | 2025 | Wegovy |
| Medtronic, INC. | $26.37 | 2024 | Percept PC Brainsense |
| Amgen INC. | $22.82 | 2024 | Uplizna |
| Aucta Pharmaceuticals, INC. | $21.09 | 2024 | Motpoly Xr |
| Neurelis, INC. | $18.75 | 2024 | Valtoco |
| Lundbeck LLC | $17.14 | 2024 | Rexulti |
| Intercept Pharmaceuticals, INC. | $16.94 | 2025 | |
| Ferring Pharmaceuticals INC. | $15.24 | 2025 | Clenpiq |
| Aimmune Therapeutics, INC. | $14.45 | 2025 | Zenpep |
| Vivus LLC | $14.15 | 2025 | Pancreaze |
| Pfizer INC. | $13.63 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binu Bashyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.